<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; regime</title>
	<atom:link href="http://www.tapanray.in/tag/regime/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Indian Patents Act To Prevail Undiluted…Finally</title>
		<link>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patents-act-to-prevail-undilutedfinally</link>
		<comments>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/#comments</comments>
		<pubDate>Mon, 27 Jul 2015 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Birdie]]></category>
		<category><![CDATA[Carlos M. Correa]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[little]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Minister. Nirmala]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nobel Laureates]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Sitharaman]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6867</guid>
		<description><![CDATA[Curiously enough, what a little birdie told me just a couple of weeks ago, very similar to that I read in various media reports even less than a week later. It was related to a somewhat trepidatious national policy in the making on &#8230; <a href="http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Clinical Trial Regime Deserves Support, Sans Threats</title>
		<link>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-clinical-trial-regime-deserves-support-sans-threats</link>
		<comments>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/#comments</comments>
		<pubDate>Thu, 30 Jan 2014 11:19:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[catalytic]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threats]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4943</guid>
		<description><![CDATA[Recent Supreme Court intervention compelling the Union Government to enforce stringent regulations both for approval and conduct of Clinical Trials (CT) in India, has unfortunately met with some strong resistance with stronger words. Some of these voices are from credible &#8230; <a href="http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Conundrum of Stringent IPR Regime in India: Responsible Pricing still remains ‘The Final Frontier’</title>
		<link>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier</link>
		<comments>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/#comments</comments>
		<pubDate>Mon, 26 Nov 2012 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[final]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[stringent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1063</guid>
		<description><![CDATA[In his management classic named, ‘The Practice of management’, published in 1954, the universal management guru Peter Drucker postulated that any successful business is driven by only the following two fundamental functions: Marketing Innovation …and all the rests are costs. &#8230; <a href="http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Early Signal of Metamorphosis in the Global Pharmaceutical Product Patent Regime</title>
		<link>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime</link>
		<comments>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/#comments</comments>
		<pubDate>Mon, 17 Sep 2012 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Early]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[signal]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=31</guid>
		<description><![CDATA[Before enactment of the Indian Patents Act (amended) 2005, it was widely reported that to protect ‘Public Health Interest’, the Parliament of India has ensured inclusion of a number of ‘safeguards’ including checks on &#8216;ever-greening&#8217; of pharmaceutical patents and broader &#8230; <a href="http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patent office (IPO) asks for details of ‘working of patents’ in India – does it herald the beginning of a new chapter in the IPR regime of the country or it could trigger another raging debate</title>
		<link>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge</link>
		<comments>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/#comments</comments>
		<pubDate>Mon, 25 Jan 2010 01:30:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[another]]></category>
		<category><![CDATA[asks]]></category>
		<category><![CDATA[beginning]]></category>
		<category><![CDATA[chapter]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[CSPDTM]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[details]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trigger]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=479</guid>
		<description><![CDATA[A Public Notice dated 24/12/2009 issued by the Controller General of Patents, Design &#38; Trade Marks, directing all Patentees and Licensees to furnish information in Form No.27 on &#8216;Working of Patents&#8217; as prescribed under Section 146 of the Patents Act &#8230; <a href="http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>We need to encourage the new product patent regime</title>
		<link>http://www.tapanray.in/we-need-to-encourage-the-new-product-patent-regime/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=we-need-to-encourage-the-new-product-patent-regime</link>
		<comments>http://www.tapanray.in/we-need-to-encourage-the-new-product-patent-regime/#comments</comments>
		<pubDate>Wed, 18 Feb 2009 04:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Encourage]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[we]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=971</guid>
		<description><![CDATA[Ushering in the Product Patent Regime in India heralds the dawn of a new era. The era that vindicates not only the need to encourage, protect and reward innovation for the rapid progress of our nation but also to compete &#8230; <a href="http://www.tapanray.in/we-need-to-encourage-the-new-product-patent-regime/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/we-need-to-encourage-the-new-product-patent-regime/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
